Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Astegolimab · 4 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Open-Label Extension | EXPERIMENTAL | Eligible participants from parent studies GB43311 and GB44332 will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W) until the end of the study |
| Astegolimab SC Q2W | EXPERIMENTAL | Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W) |
| Astegolimab SC Q4W | EXPERIMENTAL | Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving SC astegolimab Q4W. |
| Placebo SC Q2W | PLACEBO_COMPARATOR | Participants will receive SC placebo Q2W |
| Astegolimab Q2W | EXPERIMENTAL | Participants will receive subcutaneous (SC) astegolimab every 2 weeks (Q2W). |
| Astegolimab Q4W | EXPERIMENTAL | Participants will receive alternating SC astegolimab and placebo Q2W, thus receiving astegolimab every 4 weeks (Q4W). |
| Placebo | PLACEBO_COMPARATOR | Participants will receive SC placebo Q2W. |
| Treatment A | EXPERIMENTAL | Participants will receive one subcutaneous (SC) dose in the abdomen. |
| Treatment B | EXPERIMENTAL | Participants will receive one subcutaneous (SC) dose in the thigh. |
| Treatment C | EXPERIMENTAL | Participants will receive one subcutaneous (SC) dose in the upper arm. |
| Name | Type | Description |
|---|---|---|
| Astegolimab | DRUG | Participants will receive SC astegolimab Q2W |
| Placebo | DRUG | Participants will receive SC placebo Q2W |
Inclusion Criteria: * Completion of the 52-week treatment period in either parent GB43311 or GB44332 Exclusion Criteria: * Withdrawal of consent and/or premature discontinuation from parent study * Any permanent discontinuation of study drug in parent study * Significant non-compliance in the par...
Astegolimab is an investigational antibody being studied for the treatment of chronic obstructive pulmonary disease (COPD). It is currently in Phase 3 clinical trials for this condition, with studies evaluating its efficacy, safety, and long-term safety in participants with COPD.
Astegolimab is a monoclonal antibody, indicated by its -mab suffix. It is being developed by Roche to target pathways involved in COPD. The specific molecular target is not disclosed in the available information, but its mechanism is being evaluated in clinical trials for respiratory disease.
Astegolimab is developed by Roche Holding AG, a multinational healthcare company. Roche is conducting clinical trials to evaluate the drug's efficacy and safety in patients with chronic obstructive pulmonary disease (COPD).
Astegolimab is currently in Phase 3 clinical development for chronic obstructive pulmonary disease (COPD). It has completed a Phase 2 trial and is being evaluated in Phase 3 studies, including a long-term safety study, but it is not yet approved by regulatory authorities.
Astegolimab is being studied in several clinical trials, including NCT05595642, a Phase 3 study in COPD; NCT05878769, a Phase 3 long-term safety study in COPD; and NCT06462118, a Phase 1 study in healthy volunteers. A Phase 2 trial, NCT05037929, has been completed.
Astegolimab is a distinct investigational monoclonal antibody developed by Roche for chronic obstructive pulmonary disease (COPD). It is not identified as being the same as any other named drug in the available information, and its mechanism of action is being studied separately from existing COPD therapies.